Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
1.770
-0.050 (-2.75%)
Jun 20, 2025, 3:36 PM - Market open
Nkarta Employees
Nkarta had 157 employees as of December 31, 2024. The number of employees increased by 7 or 4.67% compared to the previous year.
Employees
157
Change (1Y)
7
Growth (1Y)
4.67%
Revenue / Employee
n/a
Profits / Employee
-$708,631
Market Cap
125.59M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 157 | 7 | 4.67% |
| Dec 31, 2023 | 150 | -13 | -7.98% |
| Dec 31, 2022 | 163 | 27 | 19.85% |
| Dec 31, 2021 | 136 | 41 | 43.16% |
| Dec 31, 2020 | 95 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NKTX News
- 14 days ago - Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus - GlobeNewsWire
- 5 weeks ago - Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Benzinga
- 5 weeks ago - Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 2 months ago - Nkarta to Participate in an April Investor Conference - GlobeNewsWire
- 2 months ago - Nkarta: Grinding Lower, Trying To Find Support - Seeking Alpha
- 2 months ago - Nkarta: Betting On The Turnaround - Seeking Alpha
- 3 months ago - Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
- 3 months ago - Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewsWire